following the close of the merger agreement. Mallinckrodt and Endo said the location of the combined company’s U.S. headquarters and its corporate name will be announced “in due course.” ...

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...

The proposed merger comes nearly a year after Endo emerged from bankruptcy protection. Endo Inc. has entered into an agreement to merge with Mallinckrodt in a cash and stock transaction that ...

Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.

Mallinckrodt and Endo, pharmaceutical companies that have each encountered business struggles, announced Thursday a $6.7 billion merger that they contend will result in a combined entity with the ...

The deal, which is expected to close in the second half of 2025, will see Mallinckrodt and Endo merge their portfolios of branded products, such as Mallinckrodt’s kidney disease drug Terlivaz ...

Mallinckrodt Pharmaceuticals and Endo Inc. plan to merge and create a $6.7 billion company in a move that will cut costs and broaden access to patients and new treatments. The agreement will give ...

Endo shareholders will receive $80 million in cash and own 49.9% of the combined company. After cash consideration, Mallinckrodt shareholders will own 50.1% of the combined entity on a pro ...

Mallinckrodt Pharmaceuticals plc and Endo Inc. said Thursday they are combining as part of a stock-and-cash deal with an enterprise value of $6.7 billion that will give both companies a roughly 50 ...

Mallinckrodt Pharmaceuticals and Endo Inc. are exploring a potential merger that could be valued at about $7 billion, people with knowledge of the matter said. The drugmakers, which both emerged ...

According to the 13 March announcement, the merger will create a “larger, more diversified entity”, with Mallinckrodt shareholders holding a 50.1% stake and Endo shareholders receiving 49.9% ...